SCHEMBL30522047

SCHEMBL30522047

CCc1noc2cc(OC)c(-c3ncccc3S(N)(=O)=O)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA4 P22748 1/20 0.38
▸ BRD4 O60885 6/20 0.36
▸ CA12 O43570 5/20 0.35
▸ CA2 P00918 5/20 0.35
▸ CA9 Q16790 5/20 0.35
▸ CA1 P00915 4/20 0.35
▸ GRM4 Q14833 1/20 0.35
▸ KAT7 O95251 2/20 0.35
▸ KAT6A Q92794 2/20 0.35
▸ KAT6B Q8WYB5 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ BRD2 P25440 2/20 0.33
▸ BRD3 Q15059 2/20 0.33
▸ PTGES2 Q9H7Z7 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30522048 0.85 BRD4 (0.40) CA4BRD4CA12CA2CA9
SCHEMBL30522043 0.82 CA2 (0.38) CA4BRD4CA12CA2CA9
SCHEMBL30522050 0.82 CA4 (0.39) CA4BRD4CA12CA2CA9
SCHEMBL30522049 0.81 CA2 (0.40) CA4BRD4CA12CA2CA9
SCHEMBL30522035 0.80 BRD4 (0.39) CA4BRD4CA12CA2CA9
SCHEMBL30522039 0.78 CA4 (0.38) CA4BRD4CA12CA2CA9
SCHEMBL30522040 0.78 CA4 (0.38) CA4BRD4CA12CA2CA9
SCHEMBL30522038 0.78 CA2 (0.35) CA4BRD4CA12CA2CA9
SCHEMBL30522045 0.78 CA4 (0.38) CA4BRD4CA12CA2CA9
SCHEMBL30522034 0.77 HTT (0.44) CA4CA12CA2CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113651766-B Isoxazole sulfonamide compound with BRD4 inhibitory activity, and preparation method and application thereof 泰州职业技术学院 2023-08-18 — — CN disclosed
Send feedback